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Introduction: Although bioresorbable vascular scaffolds (BVS) have been used with promising results in pa-
tients with stable and unstable angina, little is known about the acute vascular response following BVS im-
plantation in myocardial infarction. We present angiographic and OCT findings from the first patients under-
going bioresorbable vascular scaffold (BVS) implantation for non-ST-elevation myocardial infarction (NSTE-
MI) or ST-elevation myocardial infarction (STEMI) in our institution.
Methods: The first 5 patients with NSTEMI and the first 5 patients with STEMI who underwent BVS implanta-
tion in our institution, followed by optical coherence tomography (OCT) imaging of the treated culprit vessel, 
were included in this series. All patients underwent angiographic analysis pre- and post- BVS implantation, 
as well as OCT analysis, including qualitative and quantitative assessment. 
Results: Implantation was successful in all cases, as assessed by angiography and OCT. There were no 
cases with coronary spasm, distal embolization or no-reflow. No adverse clinical events were recorded in 
any patient at the 6-month follow up. Specific illustrative cases demonstrating the challenges of BVS implan-
tation in myocardial infarction are presented. 
Conclusions: BVS implantation can potentially be used in the setting of thrombotic lesions encountered in 
myocardial infarction; however, the role of this treatment approach warrants systematic evaluation in pro-
spective studies.
I mplantation of metallic platform drug-eluting stents constitutes the mainstay of revascularization in 
acute myocardial infarction.1 However, 
their use has been associated with an im-
paired vascular healing response, while 
concerns have been raised over their long-
term performance. Bioresorbable vascu-
lar scaffolds (BVS) could help overcome 
such long-term pitfalls of metallic plat-
forms.2 Although bioresorbable scaffolds 
have shown promising results in stable 
and unstable angina,3,4 the acute vascular 
response following BVS implantation in 
myocardial infarction has not been exten-
sively studied.5-7
As of September 1st, 2012, the AB-
SORB™ BVS (Abbott Vascular, Santa 
Clara, CA, USA) has been commercial-
ly available in the Netherlands. Based on 
available evidence,3,4 our department se-
lected these devices as the first option for 
younger patients presenting for percutane-
ous coronary intervention (PCI) in every-
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day clinical practice. As lesions in these patients might 
be more complex compared to those of trial investiga-
tional patients, the BVS-EXPAND registry was initi-
ated. In this registry, follow-up data are collected as 
part of the hospital routine for monitoring outcomes 
after PCI and the introduction of a different genera-
tion of stent or scaffold. The BVS-EXPAND includes 
patients with stable disease, but also patients with un-
stable angina or non-ST-elevation myocardial infarc-
tion (NSTEMI). After the first experience with acute 
patients and an interim analysis, a decision was made 
to extend BVS utilization to the treatment of ST-ele-
vation myocardial infarction (STEMI).
To assess the safety and procedural success of a 
BVS strategy in STEMI, optical coherence tomogra-
phy (OCT) imaging was performed, according to clin-
ical judgment, in patients with STEMI and BVS im-
plantation, for a more comprehensive evaluation of 
the acute procedural outcome by the operator. OCT 
is a high-resolution intravascular imaging modality 
that enables visualization of the acute vascular re-
sponse after stent implantation.8-11 Specifically, OCT 
can accurately evaluate scaffold expansion and appo-
sition, and can also assess vascular trauma and residu-
al thrombotic burden.11-13
We previously reported on a systematic analysis 
of the OCT findings post BVS implantation in STE-
MI.6 In the current report, we present patient-level 
angiographic and OCT findings from the first five pa-
tients of BVS-EXPAND presenting with NSTEMI 
and imaged by OCT, and the first five patients who 
underwent BVS implantation for STEMI followed by 
OCT imaging, in our institution, in an attempt to il-
lustrate the main challenges of BVS implantation in 
thrombotic lesions.
Methods
Study population
The current series comprised 1) the first five patients 
of BVS-EXPAND presenting with NSTEMI and im-
aged by OCT, and 2) the first five patients who un-
derwent BVS implantation for STEMI followed by 
OCT imaging, in our institution. The STEMI patients 
were not a part of BVS-EXPAND.
Procedure and OCT image acquisition
Patients with NSTEMI typically underwent coronary 
angiography within 24-72 hours from symptom on-
set, according to the regional protocol, followed by 
urgent PCI after discussion in the HeartTeam, while 
patients with STEMI underwent primary PCI upon 
hospital arrival. Interventional management, includ-
ing the use of thrombectomy, pre-dilation and post-
dilation, was performed according to the operator’s 
discretion. OCT was performed after BVS implanta-
tion using the C7™ imaging system and the Dragon-
fly™ catheter (both St. Jude Medical, St. Paul, Min-
nesota, USA), as previously described.11 In several 
cases, OCT findings guided further procedural opti-
mization (i.e. additional scaffold implantation and/
or post-dilation). In these cases, a new OCT pullback 
was performed at the end of the procedure. The pa-
tients were contacted by telephone 6 months after the 
procedure, and adverse events (death, myocardial in-
farction, any unplanned revascularization), according 
to the Academic Research Consortium definitions, 
were recorded.14
Angiographic and OCT analysis
Quantitative coronary angiography (QCA) analyses 
were performed offline by an experienced observer 
(TM) using CAAS 5.10 (Pie Medical Imaging, Maas-
tricht, Netherlands) according to a previously report-
ed methodology.13 Intracoronary thrombus was iden-
tified angiographically and scored in five grades, as 
previously described.13 Complications such as dissec-
tion, spasm, distal embolization and no-reflow were 
also recorded. OCT analysis was performed offline 
by an experienced observer in fixed 1-mm longitudi-
nal intervals within the treated culprit segment, after 
exclusion of frames with <75% lumen contour vis-
ibility. Quantitative analysis included measurement 
of the minimal lumen and the minimal scaffold area, 
according to a previously described methodology.15 
Qualitative assessment included evaluation of in-scaf-
fold and edge dissections, tissue prolapse and in-scaf-
fold thrombus. Dissections were defined as the pres-
ence of intimal discontinuity, with or without flap for-
mation, either within the scaffolded segment (intra-
scaffold dissection), or within 5-mm-long proximal 
or distal edge segments (edge dissections).16 Tissue 
prolapse was defined as the projection of tissue into 
the lumen between stent struts after implantation.16 
Incomplete strut apposition (ISA) was defined as a 
clear lack of contact between scaffold strut and vascu-
lar wall;15 apposition was assessed at a scaffold-level 
basis, using a definition of malapposed scaffold as a 
scaffold with >5% malapposed struts.
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Ethics
This was an observational study, performed according 
to the privacy policy of Erasmus MC and the Eras-
mus MC regulations for the appropriate use of data 
in patient-oriented research. These are based on in-
ternational regulations, including the declaration of 
Helsinki. A waiver from the Ethical Committee of 
Erasmus MC was obtained for written informed con-
sent, as—according to Dutch law—written consent is 
not required if patients do not undergo procedures 
other than as part of their regular treatment. Inva-
sive follow up in two of the patients was performed as 
part of an ethical committee-approved, single-center, 
investigator-driven, observational study (BVS-STE-
MI first) for which written informed consent was ob-
tained from the patients.
Results
The median patient age was 56 years (range 40-75 
years). Baseline characteristics are presented in Table 
1, while angiographic data are presented in Table 2. 
There were no cases with spasm, distal embolization 
or no-reflow. No in-hospital events were recorded. Ta-
ble 3 summarizes the OCT findings. Clinical follow-up 
at 6 months was available for all patients, showing an 
absence of adverse clinical events. Specific illustrative 
cases demonstrating the challenges of BVS implanta-
tion in NSTEMI and STEMI are presented below.
Patient 2 (Figure 1)
A 56-year-old man with no prior cardiovascular his-
tory, who presented with NSTEMI, had a total occlu-
sion of the proximal left circumflex artery (LCx) with 
collateral filling from the left anterior descending ar-
tery (LAD), as documented by coronary angiography. 
OCT imaging performed after thrombus aspiration 
and predilation with a 2.0 × 20 mm compliant Trek™ 
balloon (Abbott Vascular) revealed a thrombosed, 
severely stenotic lesion with plaque rupture and in-
timal tears, probably induced by balloon predilation 
(Panels A-D). After additional predilation with a 3.0 
× 20 mm Trek™ compliant balloon inflated at 14 atm 
(maximum diameter 3.11 mm; just below the maxi-
mum luminal diameter by QCA), a 3.0 × 18 mm BVS 
was implanted in the culprit lesion (inflation pressure 
16 atm). Following this strategy, post-implantation 
OCT showed no edge dissections or residual stenosis. 
There were, however, several sites with moderate tis-
sue prolapse/thrombus within the scaffold (panels A’-
C’), for which no additional treatment was applied.
Patient 5 (Figures 2-3)
A 56-year-old man was admitted with NSTEMI and 
referred for PCI after HeartTeam consensus. Coro-
nary angiography had demonstrated three-vessel dis-
ease: a lesion in the proximal LCx, a diffuse calcified 
lesion of the mid LAD, and a diffusely diseased right 
Table 1. Baseline and procedural characteristics.
Patient Age Sex Clinical syndrome
Lesions 
treated 
(n)
BVS 
implanted 
(n)
Thrombus 
aspiration
Balloon 
predilation BVS size
Balloon post-
dilation
Side-
branch 
dilation
Patient 1 59 ♀ NSTEMI 1 4 No 3 × 15 3 × 28, 3 × 28, 3 × 18, 2.5 × 28 3 × 12, 3.5 × 15 No
Patient 2 56 ♂ NSTEMI 1 1 Yes 3 × 20 3 × 18 No No
Patient 3 75 ♂ NSTEMI 1 3 No 3 × 15 3.5 × 18, 3 × 18,  2.5 × 18 No 1.5 × 8
Patient 4 57 ♀ NSTEMI 1 1 No 2.5 × 20 3 × 28 No No
Patient 5 56 ♂ NSTEMI 2 3 No
3 × 15 (LCx)
3 × 20 
(LAD)
3.5 × 18, 3.5 × 12 
(LCx)
3.5 × 28 (LAD)
No (LCx)
3.75 × 15 (LAD) No
Patient 6 56 ♀ STEMI 1 1 Yes 2.5 × 20 3 × 28 3.25 × 15 No
Patient 7 40 ♂ STEMI 1 1 Yes 2.5 × 15 3.5 × 18 No No
Patient 8 53 ♂ STEMI 1 1 No 2 × 8 2.5 × 18 No No
Patient 9 65 ♂ STEMI 1 2 Yes No 3.5 × 12, 3.5 × 12 4 × 8 No
Patient 10 58 ♂ STEMI 1 2 Yes 3 × 12 3.5 × 18, 3.5 × 18 3.5 × 15 1.5 × 15
BVS – bioresorbable vascular scaffold; NSTEMI – non-ST-elevation myocardial infarction; STEMI –  ST-elevation myocardial infarction; LCx  –  left 
circumflex artery; LAD – left anterior descending artery.
128 • HJC (Hellenic Journal of Cardiology)
A. Karanasos et al
coronary artery (RCA). It was decided to proceed 
with LCx and LAD revascularization, and staged re-
vascularization of the RCA one month later.
The proximal LCx lesion (Panel 2I) was treated 
by 3.5 × 18 mm BVS implantation and post-dilation 
with a 3.0 × 15 mm compliant Trek™ balloon (Panel 
2II). Subsequently, lumen narrowing with haziness 
was observed proximally, corresponding to an edge 
dissection by OCT (Panels 2A-B). The dissection was 
treated by implantation of an overlapping 3.5 × 12 
mm BVS with a good angiographic result (panel 2III). 
A final OCT pullback showed focal under-expansion 
due to calcification, as well as sites with mild tissue 
prolapse and in-stent thrombus (Panels 2A’-D’).
The LAD lesion (Panel 3I) was treated by 3.0 
× 20 mm Trek™ balloon predilation, 3.5 × 28 mm 
BVS implantation and post-dilation with a 3.75 × 
15mm Trek™ non-compliant balloon (Panels 3II-III). 
OCT following predilation revealed a heavily calci-
fied vessel without intracoronary thrombus. Post-im-
plantation OCT demonstrated good scaffold apposi-
tion, moderate pinching of the ostium of the diagonal 
(Panel 3A’), focal under-expansion at sites with heavy 
calcification (Panel 3C’), lack of tissue prolapse, and 
a small distal edge dissection (Panel 3D’).
Patient 7 (Figure 4)
A 40-year-old man with diabetes and no known car-
diovascular history was admitted with anterior STE-
MI. Angiography demonstrated a stenotic LAD le-
sion with angiographic haziness (Panel I). The le-
sion was treated by thrombus aspiration, 2.5 × 15 mm 
Trek™ compliant balloon pre-dilation and 3.5 × 18 
mm BVS implantation (Panels II-III). A small edge 
dissection was visible by angiography after implanta-
tion. OCT confirmed the diagnosis of distal edge dis-
section extending for ~5 mm, which was left untreat-
ed (Panels D-E). The scaffold was well-expanded and 
apposed with moderate tissue prolapse and in-scaf-
fold thrombus at the middle segment (Panels A-C). 
The patient underwent invasive follow up, including 
OCT imaging, 9 months post implantation for study 
purposes (Panel IV). The follow-up OCT showed a 
good healing response, without late ISA, high strut 
coverage (Panels A’-C’) and complete healing of the 
dissection with integration of the dissection flap in 
the vessel wall (Panels D’-E’).
Patient 8 (Figure 5)
A 52-year-old man with an unremarkable cardiovas-
cular history was admitted with anterolateral STE-
MI. Angiography demonstrated total occlusion of 
the second diagonal branch (Panel I). The lesion was 
treated by 2.0 × 8 mm Trek™ compliant balloon di-
lation and 2.5 × 18 mm BVS implantation (Panels 
II-III). OCT showed a well-expanded and apposed 
scaffold with no vascular trauma at the middle and 
distal segments, and mild tissue prolapse and throm-
bus near the vessel ostium (Panels C-D). Scaffold 
struts were visible at the polygon of confluence of 
Table 2. Angiographic characteristics.
Patient Culprit vessel
Pre procedure Pre BVS implantation Post implantation (in-scaffold)
Total 
Occlusion
Thrombus 
burden
Dmax 
(mm)
RVD 
(mm)
MLD 
(mm)
DS 
(%)
RVD 
(mm)
MLD 
(mm)
DS 
(%)
Final 
TIMI 
flow
Dissection
Patient 1 RCA Yes 5 3.6 2.64 1.04 61 2.76 2.22 20 ΙΙ Yes
Patient 2 LCx Yes 5 3.22 2.74 2.1 23 3.15 3 5 III No
Patient 3 LAD No 2 3.16 2.18 1.56 28 2.51 2.32 8 III No
Patient 4 LAD No 1 3.09 2.74 1.22 55 2.79 2.46 12 III No
Patient 5, Lesion 1 LCx No 0 3.44 2.96 1.39 53 2.71 2.36 13 III No
Patient 5, Lesion 2 LAD No 0 3.28 3.27 1.27 61 2.81 2.54 10 III No
Patient 6 RCA Yes 5 3.44 2.89 0.96 67 2.85 2.42 15 III Yes
Patient 7 LAD No 2 3.16 2.68 2.16 19 2.92 2.92 0 II Yes
Patient 8 LD Yes 5 2.55 2 0.51 74 2.47 2.05 17 III No
Patient 9 RCA Yes 5 3.97 3.52 1.4 60 3.17 2.39 25 III No
Patient 10 LAD No 3 3.63 2.29 0.9 61 2.58 1.93 25 III No
Dmax – maximum diameter; RVD – reference vessel diameter; MLD – minimum lumen diameter; DS – diameter stenosis; RCA – right coronary artery; LD 
– diagonal branch. Other abbreviations as in Table 1.
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the LAD-diagonal bifurcation, with minimal protru-
sion of the scaffold into the LAD (Panels A, B, G). 
Invasive follow up with OCT imaging was performed 
1 year post implantation for study purposes (Panel 
IV). The follow-up OCT revealed a good healing re-
sponse without ISA and a low number of uncovered 
struts (Panels A’-D’). Dense tissue coverage was also 
observed at the side-branch-related struts located in 
the vessel ostium, resulting in the development of a 
neo-carina (Panel H).
Table 3. Optical coherence tomography (OCT) findings.
Patient ISA
Minimal 
lumen area 
(mm2)
Minimal 
scaffold 
area (mm2)
Intraprocedural findings Final OCT findings
Patient 1 Yes Proximal BVS: 6.63
Proximal 
BVS: 7.85
Extensive intra-scaffold 
dissections with ISA in 
proximal scaffold, treated 
with post-dilation
•	 Improvement of scaffold apposition after post-dilation.
•	Minimal tissue prolapse.
Patient 2 No 7.60 8.34 -
•	Good expansion and apposition.
•	No edge dissections
•	Moderate tissue prolapse/thrombus.
Patient 3 Yes 4.42 4.97 Side-branch compromise, treated with balloon dilation
•	Distal and middle scaffolds well-expanded without tissue 
prolapse or thrombus.
•	 ISA in the proximal and middle scaffolds due to 
eccentric calcium and intra-scaffold dissections.
•	Mild tissue prolapse in the proximal scaffold.
•	No evident scaffold fracture at the level of the side-
branch.
Patient 4 No 6.05 6.57 -
•	Good expansion and apposition without edge 
dissections.
•	Short segment with moderate tissue prolapse/thrombus
Patient 5
LCx: 
Yes
LAD: 
No
LCx: 6.28 
mm2
LAD: 4.98 
mm2
LCx: 6.28 
mm2
LAD: 5.36 
mm2
Proximal dissection in LCx, 
treated with 2nd BVS
•	LCx: mild tissue prolapse/thrombus in both scaffolds.
•	Sub-optimal expansion and ISA focally.
•	LAD: good apposition with sub-optimal expansion 
focally due to calcium.
•	Small distal edge dissection.
Patient 6 Yes 6.27 7.07
Extensive intra-scaffold 
dissection with ISA, treated 
with post-dilation.
•	Reduction of dissection cavity size and malapposition 
distance after post-dilation.
•	Mild tissue prolapse and in-scaffold thrombus ISA.
Patient 7 No 7.55 8.33 -
•	Distal edge dissection ~5 mm long.
•	Sites with moderate tissue prolapse/in-scaffold thrombus 
proximally.
Patient 8 No 4.21 4.76 -
•	Well-expanded and apposed scaffold with minimal tissue 
prolapse/thrombus.
•	Scaffold protrusion into the main branch for ~1 mm.
Patient 9 Yes 5.72 7.6
Stenosis in distal RCA after 
BVS implantation in RPL, 
treated with 2nd BVS.
•	 ISA proximally due to scaffold-lumen dimensions 
mismatch. 
•	Minimal overlap at the crux with moderate tissue 
prolapse.
•	Presence of struts at the RPD ostium and residual red 
thrombus.
Patient 10 No 6.77 7.15
Small edge dissection and 
residual lesion distally 
(MLA: 1.71 mm2), treated 
with 2nd BVS - Side-branch 
compromise, treated with 
balloon dilation
•	Good expansion and apposition with minimal overlap.
•	Mild tissue prolapse/thrombus in both scaffolds.
•	No evident scaffold fracture at the level of the side-
branch.
ISA – incomplete scaffold apposition; RPL – right posterolateral branch; RPD – right posterior descending branch; MLA – minimal lumen area. Other 
abbreviations as in Tables 1 and 2.
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Discussion
The current series of patients provides real-life in-
sights into the acute vascular response after BVS im-
plantation in myocardial infarction. In order to assess 
the efficacy of BVS implantation, OCT imaging was 
employed. OCT-derived parameters can potentially 
be used as surrogate markers for assessing the acute 
outcome of BVS implantation in patients with myo-
cardial infarction. In particular, in addition to the as-
sessment of luminal dimensions and scaffold expan-
sion, OCT allows a comprehensive assessment of the 
scaffold-vessel wall interaction, providing detailed in-
formation about scaffold apposition, vascular trauma 
(intra-scaffold and edge dissections, tissue prolapse), 
and residual thrombotic burden. The clinical impact 
of such OCT parameters has not been established; 
however, their evaluation in studies of BVS implanta-
tion in myocardial infarction could be of significance, 
considering i) the increased incidence of incomplete 
apposition after metal stent implantation in myocar-
dial infarction,17 ii) the need for more aggressive le-
sion preparation with BVS, and iii) the association of 
increased residual thrombus with impaired reperfu-
sion after metal stent implantation in myocardial in-
farction.18
In the ABSORB B study, in a relatively non-com-
plex lesion subset of patients with stable and unstable 
Figure 1. Top panels: Coronary angiography demonstrating the culprit lesion of the proximal left circumflex artery (I) pre-intervention, 
(II) after 2.0 mm balloon predilation, (III) after 3.0 mm balloon predilation, and (IV) after 3.0 × 18 mm bioresorbable vascular scaffold 
(BVS) implantation. Black arrows indicate scaffold markers, and white lines the sites corresponding to the bottom panels. Bottom panels: 
Culprit lesion optical coherence tomography images of matched sites (A-D) after 2.0 mm balloon dilation and (A’-D’) after BVS implanta-
tion. Pre-implantation images demonstrate (A) plaque rupture with cavity, (B) minimal lumen area with red thrombus, (C) dissection flap, 
and (D) distal segment with macrophage infiltration. Findings after BVS implantation include (A’) mild tissue prolapse at the cavity site, 
(B’) residual compressed red thrombus, (C’) tissue prolapse at the site of the flap, and (D’) good expansion and apposition without tissue 
prolapse/thrombus.
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angina, the BVS has shown adequate expansion, with 
a minimum scaffold area of 6.31 ± 1.25 mm2.15 In our 
series of patients with myocardial infarction, good 
scaffold expansion was observed in all but one case, 
in which case the implanted scaffolds were focally un-
der-expanded because of heavy calcification (Panels 
2C’ and 3C’). In all other patients the implanted scaf-
folds were well expanded, including a case with direct 
BVS implantation in STEMI (Patient 9).
Apposition was not optimal in all cases, with 
causes for incomplete apposition including extensive 
intra-scaffold dissections and in one case mismatch of 
lumen and scaffold dimensions after bail-out BVS im-
plantation in a proximal segment (Patient 9). The se-
lection of scaffold size during the acute phase of myo-
cardial infarction can be challenging, as the increased 
thrombus burden and the enhanced vascular tone can 
hamper evaluation of the true vessel size.12 Post-dila-
tion guided by OCT imaging—always in agreement 
with scaffold compliance and respecting the recom-
mended maximum scaffold diameter—helped im-
prove scaffold apposition in most cases. Still, the fu-
ture course of scaffold apposition remains elusive. In 
the two patients in our series who underwent inva-
sive follow up, no late incomplete scaffold apposition 
was observed. Although implantation of metal stents 
during primary PCI is associated with higher incom-
plete apposition at follow up compared to stable an-
gina,8,17 possibly due to resolution of vasoconstriction 
and thrombus,12 no such data are currently available 
for the follow up of BVS implanted in myocardial in-
farction. Thus, longer-term follow up and prospective 
Figure 2. Top panels: Coronary angiography demonstrating the left circumflex artery lesion (I) pre-intervention, and (II) after 3.5 × 18 
mm bioresorbable vascular scaffold (BVS) implantation. Because of proximal dissection a 3.5 × 12 mm scaffold was implanted (III). Black 
arrows indicate scaffold markers, and white lines the sites corresponding to the bottom panels. Bottom panels: Culprit lesion optical coher-
ence tomography images of matched sites after (A-D) first and (A’-D’) second BVS implantation. In the proximal scaffold, there is tissue 
prolapse at the sites of the dissection flaps with a small amount of intraluminal thrombus (A-A’, B-B’). Mild under-expansion over a calci-
fied plate (C-C’) and mild tissue prolapse/in-stent thrombus (D-D’) are observed at the distal scaffold. 
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studies are warranted to assess the true extent of in-
complete scaffold apposition in myocardial infarction 
and its clinical implications at follow up.
Despite their similar pathophysiological mecha-
nisms, NSTEMI and STEMI exhibit differences in 
lesion morphology and disease severity.19,20 In our 
series, high disease heterogeneity was observed in 
NSTEMI. Two of the cases with NSTEMI (Patients 
1 and 2) presented with total occlusion. Implantation 
was successful in both cases with a good final result, 
demonstrating the potential of BVS implantation in 
a highly thrombogenic setting, similar to STEMI. In-
deed, the vascular response after BVS implantation 
in STEMI resembled these NSTEMI cases. The other 
end of the NSTEMI spectrum also includes patients 
with multiple lesions, increased calcification and min-
imal thrombus, as in Patient 5. Conversely, all STEMI 
cases in our series were associated with angiographic 
thrombus, dictating the use of thrombus aspiration in 
all but one case.
The different lesion substrate could have impli-
cations for the extent of vascular trauma and residual 
thrombotic burden. Both lesion morphology and un-
stable presentation have been associated with peri-
procedural vascular trauma.9 In cases with heavy cal-
cification, as in Patient 5, aggressive lesion prepara-
tion could help optimize scaffold expansion. How-
ever, lesion preparation should be performed with 
caution, as it may as well induce extensive vascular 
trauma, as in Patients 1 and 6.21 Predilation has been 
associated with increased distal embolization in the 
setting of metal stent implantation for myocardial in-
Figure 3. Top panels: Coronary angiography demonstrating the LAD lesion (I) pre-intervention, (II) after 3.0 mm balloon dilation, and 
(III) after 3.5 × 28 mm bioresorbable vascular scaffold (BVS) implantation and post-dilation with 3.75 mm non-compliant balloon. Black 
arrows demonstrate scaffold markers and white lines the sites corresponding to the bottom panels. Bottom panels: Culprit lesion optical 
coherence tomography images of matched sites after (A-D) pre-dilation and (A’-D’) BVS implantation. (A-A’) Small thrombus formation 
and pinching of the diagonal ostium post-implantation. (B-B’) Good expansion and apposition at the site of a dissected eccentric calcified 
plaque. (C-C’) Suboptimal scaffold expansion due to the presence of two protruding calcified plates at a site without dissection. (D-D’) 
Small distal edge dissection at the site of a calcified nodule. LAD – left anterior descending branch; LD – diagonal branch.
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farction,22 however such data are not available for 
BVS. In our series, although distal embolization was 
not angiographically documented, OCT revealed 
varying degrees of tissue prolapse and/or residual 
thrombus in all cases. Importantly, increased tissue 
prolapse and/or residual thrombus have been associ-
ated with impaired reperfusion following stenting for 
STEMI.18 Therefore, it is important to evaluate such 
findings systemically in BVS and to assess their sig-
nificance and differences with metal platform stents.6
Another important aspect is the presence of cul-
prit bifurcation lesions. In cases of ostial side-branch 
disease, as in Patients 8 and 9, BVS implantation con-
stitutes an appealing option, given the favorable re-
sponse observed in side-branch-related scaffold struts, 
with their gradual replacement by tissue bridges and 
development of a neo-carina,23 Conversely, in metal 
stents, the permanent stent layer jailing side-branches 
is often characterized by impaired healing,24 providing 
a potential substrate for thrombosis. In the case of cul-
prit lesions with large side-branch involvement, how-
ever, a high thrombus burden can cause underestima-
tion of the side-branch involvement, potentially re-
sulting in side-branch compromise post-procedurally, 
as in Patients 3 and 10. The good angiographic result 
after side-branch dilation and the absence of scaffold 
fracture by OCT suggest a potential role for this ap-
proach in the treatment of side-branch compromise.
It is important to note that the current series repre-
sents a preliminary report of a single-center experience 
with BVS implantation in myocardial infarction. The 
current report did not aim to conduct a systematic analy-
sis of the OCT findings, but instead gives patient-specif-
ic descriptions of the acute vascular response, aiming to 
provide initial observations and demonstrate challeng-
es and differences with stable disease. The impact of a 
thrombotic substrate on the vascular response following 
BVS implantation still needs to be systematically evalu-
ated in larger patient cohorts with a longer follow up.
Conclusions
In the current series, we presented angiographic and 
OCT findings following BVS implantation in myocar-
dial infarction. Implantation was successful both in 
thrombotic culprit lesions of NSTEMI patients and in 
culprit lesions of STEMI patients, with a similar acute 
vascular response by OCT. The incidence of incom-
Figure 4. Top panels: Coronary angiography demonstrating the culprit left anterior descending artery lesion (I) pre-intervention, (II) post 
thrombus	aspiration/2.5	mm	balloon	predilation,	(III)	post	3.5	�	18	mm	BVS	implantation,	and	(IV)	at	9-month	follow	up.	Black	arrows	
indicate scaffold markers and white lines the sites corresponding to the bottom panels. Bottom panels: Optical coherence tomography of 
the treated lesion. Panels A-C disclose the presence of varying degrees of tissue prolapse/intra-scaffold thrombus, and Panel D an intra-
scaffold dissection. Nine-month follow-up images show a favorable healing response with the absence of late incomplete apposition, sym-
metric coverage of the bioresorbable vascular scaffold (A’-C’), and the complete healing of the edge dissection (D’). L-mode images at 
baseline (E) and follow up (E’) demonstrate the longitudinal morphology of the healed dissection (arrow).
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Figure 5. Top panels: Coronary angiography demonstrating (I) total occlusion of the LD, and the angiographic result after (II) 2.0 mm 
balloon predilation and (III) 2.5 × 18 mm bioresorbable vascular scaffold  implantation. Panel IV shows the angiography at 12-month 
follow up. Black arrows indicate scaffold markers and white lines the sites corresponding to the bottom panels. Bottom panels: Optical 
coherence tomography (OCT) of the culprit diagonal branch lesion. Scaffold struts are protruding into the polygon of confluence of the 
LAD-diagonal bifurcation, as can appreciated from both the LAD (A, E) and the diagonal pullback (B, F). There is mild tissue prolapse 
and thrombus near the vessel ostium (C), but minimal prolapse in the middle and distal scaffold segments, with good expansion and ap-
position (D). Follow-up OCT images at matched sites are presented in panels A’-D’, showing coverage of the implanted scaffold, absence 
of incomplete apposition, and the development of tissue bridges in relation to side-branch-related struts. Three-dimensional renderings 
illustrate the development of a neo-carina at the site of scaffold protrusion into the LAD (E, E’). LAD – left anterior descending branch; 
LD – diagonal branch.
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plete scaffold apposition at follow up, the role of the 
pathological substrate in the selection of lesion prep-
aration strategy, and the impact of periprocedural 
trauma and residual thrombus post-intervention re-
main open questions regarding BVS implantation in 
myocardial infarction that warrant systematic evalua-
tion in prospective studies.
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